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Abstract
Broadly neutralizing monoclonal antibodies effective against the majority of circulating isolates of HIV-1 have been isolated
from a small number of infected individuals. Definition of the conformational epitopes on the HIV spike to which these
antibodies bind is of great value in defining targets for vaccine and drug design. Drawing on techniques from compressed
sensing and information theory, we developed a computational methodology to predict key residues constituting the
conformational epitopes on the viral spike from cross-clade neutralization activity data. Our approach does not require the
availability of structural information for either the antibody or antigen. Predictions of the conformational epitopes of ten
broadly neutralizing HIV-1 antibodies are shown to be in good agreement with new and existing experimental data. Our
findings suggest that our approach offers a means to accelerate epitope identification for diverse pathogenic antigens.
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Introduction
HIV afflicts 34 million people worldwide, with the highest
infection rates concentrated in sub-Saharan Africa [1]. Although
antiretroviral therapy has done much to alleviate the burden of
HIV infection in the developed world, a prophylactic vaccine still
remains the best hope of controlling the epidemic, particularly in
the developing world [2].
Effective vaccines induce neutralizing antibodies that protect
the host by binding to the infectious pathogen and/or infected cells
[3,4,5,6]. For HIV, passive administration of neutralizing
antibodies can prevent chimeric simian-human immunodeficiency
virus from establishing infection in non-human primates
[7,8,9,10,11,12,13], suggesting that the induction of such antibod-
ies should be a major goal of HIV vaccine research. However, the
high antigenic variability of HIV is a major roadblock to eliciting
effective antibody responses by vaccination [14,15]. Nevertheless,
renewed hope has emerged with the isolation of potent, broadly
neutralizing monoclonal antibodies (bnMAbs) effective against
diverse HIV-1 subtypes from a small number of HIV-positive
persons, suggesting that the adaptive immune system is capable of
generating broadly neutralizing antibody responses [16,17].
The target of HIV-1 bnMAbs is the surface glycoprotein, Env,
which natively exists as a trimer comprising three gp120 and three
gp41 glycoprotein molecules in non-covalent association [18]. The
viral spike binds to the receptor, CD4, and a chemokine co-
receptor on T-lymphocytes, and mediates viral entry into host cells
[19].
A number of studies have focused on the development of a
deeper understanding of the properties and neutralization targets
of bnMAbs to provide insight and guidance for rational
immunogen design [17,18]. An important aspect of defining the
antigenic target sites is the identification of newly isolated bnMAb
binding sites (epitopes) on the Env spike. Current experimental
techniques for monoclonal antibody (MAb) epitope mapping such
as peptide scanning [20], phage-display [21], and site-directed and
‘‘shotgun’’ mutagenesis [22] are typically expensive and/or labor-
intensive. Targeted mutational scans limited to residues within
likely antibody binding sites requires a pre-existing knowledge of
common antibody epitopes, which, for viruses less well-studied
than HIV, may be unavailable. Furthermore, such targeted
approaches are unable to identify novel epitopes bound by
previously uncharacterized bnMAbs. Computational epitope
prediction offers an inexpensive means to localize epitopes within
the protein structure, providing potentially valuable information to
target experimentation, and substantially reduce the time and
expense of epitope identification [23,24,25].
Computational prediction of Env epitopes from sequence data
alone has shown limited success [26,27,28]. A particular difficulty
PLOS ONE | www.plosone.org 1 December 2013 | Volume 8 | Issue 12 | e80562facing these approaches is that the preponderance of antibody
epitopes are not formed from linear regions of the protein chain,
but are conformational in nature, comprising non-contiguous
regions brought together in the three-dimensional structure
[29,30]. Despite significant advances in recent years, the
‘‘predictive performance of current methods is far from ideal’’
[29] even in instances where the three-dimensional antigen (Ag)
structure is available [29,30,31,32]. Partial structures for gp120
and gp41 have been previously reported [33,34], but only very
recently has the structure of the unliganded trimer been
determined by cryo-EM [35]. The ,11 A ˚ resolution, however,
prohibits unambiguous identification of the individual residues
constituting potential antibody binding sites.
Combined approaches employing computational algorithms to
map experimental peptide phage display binding data to the
surface of an Ag structure have enjoyed greater success [29]. The
Mapitope algorithm, for example, has predicted gp120 epitopes
for several HIV MAbs that are in good accord with experimental
data [25,36,37]. Such approaches, however, require the availabil-
ity of both peptide binding data and the Ag structure, making
them unsuitable for the definition of epitopes in systems where
high resolution protein structures are difficult, or expensive, to
obtain.
Here, we develop a computational approach to predict
particular residues within MAb conformational epitopes by
analyzing experimental neutralization activity data against a panel
of viral strains. Cross-clade neutralization activity is generally
collected in the analysis of new HIV bnMAb isolates, making our
epitope prediction approach well-suited to ‘‘piggyback’’ existing
experimental data sets, without relying on structural information
or necessitating additional experimental characterization. These
residues predicted by our approach are expected to be those within
the conformational epitope that are most important in determin-
ing MAb neutralization efficiency. Our approach relies on
knowledge of the sequences of the viral strains within the panel,
but does not require structural information.
Multivariate regression models and machine learning tech-
niques have been widely applied to peptide binding data to build
and train predictive models of linear peptide binding affinities to
T-lymphocytes [23,27,32,38]. We do not seek to construct
quantitative models of conformational epitope binding affinities
for MAbs. Rather, we wish to identify residues that form part of
the MAb epitope that are the primary determinants of its
neutralization activity. Toward this end, we draw on techniques
from compressed sensing [39] and information theory [40] to serve
as variable selection tools.
Compressed sensing (CS) is a framework that enables the
recovery of sparse signals from far fewer measurements than
conventional approaches [39,41], and has been applied to great
effect in diverse areas including the design of protein-DNA
potential functions [41], face recognition [42], and the ‘‘single
pixel camera’’ [43]. In the present case, a ‘‘measurement’’
corresponds to the neutralization activity of a particular bnMAb
against a particular viral strain, and ‘‘signal’’ corresponds to the
influence of each amino acid residue in the strain upon the
antibody neutralization efficiency. Since bnMAb epitopes typically
comprise only a small number of residues, the impact of most
positions within the protein upon MAb neutralization is expected
to be small, leading to naturally sparse signals. Furthermore, the
number of viral strains against which neutralization activity
measurements are available is expected to be small compared to
the number of positions in the protein. Accordingly, compressed
sensing presents a powerful framework for the identification of the
residues constituting bnMAb epitopes from limited data.
The mutual information (MI) is an information theoretic concept
that quantifies the information that one random variable, or group
of variables, X, contains about another, Z [44]. Equivalently, it
provides a measure of the reduction of the uncertainty in Z given
knowledge of X [44]. The MI is a model-free measure that does
not require any a priori assumptions about the form of the
relationship between X and Z, and can therefore be used to detect
both linear and nonlinear associations [40]. The MI has previously
been used in variable selection algorithms in the context of protein
contact site prediction [45,46] and spectroscopic modeling [40]. In
the present work, the identity of the amino acid residue at most
positions in the protein is expected to possess low information
content about bnMAb neutralization activity. Only for the small
number of residues comprising the bnMAb epitope is this
information content expected to be high. Accordingly, the mutual
information presents a natural means to identify residues
constituting bnMab epitopes.
The new computational methodology described in this work is
the development of two classifiers based on compressed sensing
(CS) and mutual information (MI) to identify residues constituting
antibody epitopes by analyzing experimental neutralization
activity data. We combine the predictions of these two approaches
into a single ensemble classifier that is expected to possess better
classification performance than either classifier alone [38,47,48].
The details of our approach are described in Materials and
Methods.
Our approach can identify residues constituting the epitope that
may be remote in the primary protein sequence. In that sense, it is
capable of identifying conformational (or discontinuous) epitopes [29].
As is the case for all sequence-based approaches, however, in the
absence of structural information our technique identifies functional,
rather than structural, epitopes [31]. Studies have shown that
functional epitopes typically comprise between three and five
residues [31,49]. While it is typically expected that residues
comprising the structural epitope of the bnMAb will have the
largest impact on neutralization activity [50], it is possible that
point mutations at residues structurally remote from the antibody
binding site may impart long-ranged conformational perturbations
that substantially influence binding efficiency. Indeed, as we
discuss below, our technique identifies for one bnMAb considered
in this study (PGT-130) a residue in the gp41 C-terminal tail that
may influence binding via long-ranged non-covalent associations.
Furthermore, we assume that each MAb binds to a single antigenic
epitope; experimental work has shown this to be the case for all
bnMAbs considered in this work [51].
Results
In Tables 1, 2, 3 we present the Env residues identified by our
compressed sensing, mutual information, and ensemble classifiers
as important discriminants of neutralization activity for the ten
HIV-1 bnMAbs considered in this study by computational analysis
of experimental neutralization activity data against a panel of 141
viral strains (cf. Materials and Methods). The NCBI accession
numbers and measured neutralization activities of the 141 strains
are provided in Table S1. For nine of the ten bnMAbs, our
ensemble classifier predicts between one and three positions to
form part of the bnMAb epitope. For the remaining bnMAb –
PGT-125– the ensemble classifier fails to identify any positions,
due to an absence of consensus between the CS and MI classifiers.
We generically observe for all bnMAbs in this study that the CS
classifier identifies many more positions than the MI. We attribute
this observation to the fact that whereas the MI classifier seeks to
perform classification of sequences for neutralized and non-
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PLOS ONE | www.plosone.org 2 December 2013 | Volume 8 | Issue 12 | e80562Table 1. Compressed sensing (CS), mutual information (MI), and ensemble classifier predictions of HIV-1 Env positions constituting
bnMAb epitopes for PGT 123, 123, 125, and 126.
bnMAb CS classifier MI classifier Ensemble classifier Experiment
nCS position residue nMI position nENS position nEXPT position
PGT-121 4 323 Ile 3 332 1 332 2 332
330 His 334 334
332 Asn 475
843 Val
PGT-123 10 323 Ile 3 330 3 330 3 325
330 His 332 332 332
332 Asn 334 334 334
334 Asn
334 Ser
612 Ser
671 Asn
740 Gln
815 Val
843 Val
PGT-125 27 82 Arg 1 332 0 – 2 301
136 Ser 303
165 Ile
188 Asn
230 Asn
276 Asn
289 Val
290 Arg
297 Thr
300 Ser
323 Ile
325 Asp
334 Ser
442 Glu
465 Thr
513 Val
520 Leu
632 Asp
674 Asn
721 Phe
746 Thr
769 Arg
792 Ala
815 Val
817 Ala
840 Phe
841 Leu
PGT-126 6 297 Thr 3 297 3 297 4 301
332 Asn 332 332 303
334 Ser 334 334 332
373 Thr 334
442 Glu
842 Asn
Computational Prediction of HIV Antibody Epitopes
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least squares fit to a continuous observation, the neutralization
activity. Abstracting the neutralization activity to a binary variable
(neutralized vs. non-neutralized) eliminates degrees of freedom,
reducing the complexity of the problem from curve fitting to
binary classification. Concomitantly, the MI classifier appears
capable of performing its classification task using fewer variables.
A generalized version of our MI classifier could accept
neutralization activity data discretized into more than two
categories (e.g., non-neutralized, weakly neutralized, strongly
neutralized). It would be interesting to explore the impact of the
number of bins, and bin cutoffs, upon the positions, and number of
positions, identified by the MI classifier.
To compare our predictions to experimental data, we also
report in Tables 1, 2, 3 those positions identified by single-alanine
substitutions in the Env of JR-CSF pseudovirus to significantly
impact the measured neutralization activity – specifically, those
that cause a more than 30-fold increase in the measured IC50
concentration (cf. Materials and Methods) – providing experi-
mental evidence that these positions form part of the bnMAb
epitope [51].
To assess the robustness of our predictions to the size of the
panel of viral strains, we applied our approach to independently
selected random subsets of the 141 viral strains. In Table S2 we
present the predictions of the ensemble classifier to neutralization
activity data against 35, 70, 105, and 126 viral strains, respectively
constituting 25%, 50%, 75%, and 90% of the 141-strain
pseudovirus panel. Subsampling – or alternatively bootstrapped
resampling – of the pseudovirus panel provides a means to assess
the robustness of the predictions to the data, and determine
whether the panel is sufficiently large to generate statistically
reliable predictions. Only one of the predictions made using the
25% panel is in accord with those made over the full data set. At
50%, predictions for four of the ten bnMAbs are in agreement.
The 75% and 90% results are in good accord with the predictions
made over all 141 strains, differing by at most one predicted
position, with the single exception of the PGT-126 75% result that
differs by two. These results indicate that our predictions are
robust to the precise composition of the pseudovirus panel, and
reliable predictions can be made from neutralization activity
measurements for ,100 viral strains.
We now proceed to compare our predictions of key epitope
residues to previously reported [51] and new experimental
evidence for all ten bnMAbs. For two bnMAbs, PGT 143 and
145, we directly tested our computational predictions by
performing alanine scans at the identified positions. We emphasize
that experimental testing of our computational predictions for
these two bnMAbs was performed after making our computational
predictions. Details of the alanine scan studies performed for PGT
143 and 145 constitutes new experimental data to be fully detailed
in an upcoming publication.
Prior Experimental Characterization
Previous experimental work has demonstrated that bnMAbs
PGT 121, 123, 125–128, 130, and 135 all bind to monomeric
gp120 in enzyme-linked immunosorbent (ELISA) assays, and
compete with the glycan-specific bnMAb 2G12 for binding to
monomeric gp120 in ELISA assays [51]. Alanine scans have
demonstrated that PGT-135 binds residues within both the V3
and V4 loops of gp120, with the N-linked glycans at positions 332
and 392 particularly important to neutralization activity [51]. All
of the seven remaining PGT bnMAbs (PGT 121, 123, 125–128,
and 130) were shown to compete with a V3-loop-specific bnMAb,
failed to bind a gp120 mutant missing the V3 loop, and possessed
neutralization activities strongly dependent on N-linked glycans at
positions 301 and/or 332 [51]. These results strongly suggest that
PGT 121, 123, 125–128, and 130 bind to a tertiary epitope
involving the V3 loop of the gp120 chain that partially comprises,
or is configurationally dependent upon, the N-linked glycans at
positions 301 and 332, determined by the consensus sequence
NXT/S [51,52].
PGT 121, 123, 126, 127, 128, 135:332 N-glycan Dependent
bnMAbs
A JR-CSF pseudovirus containing single alanine substitutions at
positions 332 and 334 in the V3 loop significantly impacted
neutralization by PGT 121, 123, 126, 127, and 135 [51]. As is
apparent from Tables 1, 2, 3, the residues predicted by our
ensemble classifier are in good agreement with the experimental
results for these five bnMAbs. For PGT 123 and 126, it also
identifies residues 330 and 297, respectively, as proximate
positions implicated in binding.
For PGT-128, our ensemble classifier also identified positions
332 and 334. While the neutralization activity for the isolate JR-
CSF was not sensitive to alanine mutation at position 332 [51], our
predictions are supported by the crystal structure of PGT-128
bound to an engineered glycosylated gp120 outer domain
(containing a JR-FL mini-V3 loop) which revealed the importance
of positions 332 and 301 for binding [52].
In the cases of PGT 121 and 135, the ensemble classifier does
identify the N-linked glycan: identifying position 332 directly for
PGT-121, and position 334, which would remove the glycan at
332, for PGT-135. It does not, however, detect both of these
positions, and it is possible that the strong pairwise correlations
between these two residues may be frustrating the simultaneous
identification of the pair. For example, it is known that for groups
of variables containing strong pairwise correlations the LASSO
algorithm implemented in the CS classifier may identify only one
variable from the group [53]. We observe that more advanced
versions of the LASSO algorithm [53], or dynamic variable
selection routines for the MI classifier [40] may exhibit improved
group selection characteristics.
The experimentally identified positions are defined as those at which alanine point mutations were observed to increase the measured IC50 of the mutant by more than
30-fold relative to that of the wild type JR-CSF. Alanine scans were performed as part of the present work for PGT 143 and 145; data for PGT 121–135 were taken from
Ref. [51].
Footnote: For each of the ten HIV-1 broadly neutralizing monoclonal antibodies (bnMAb) considered in this study, we report the residues identified by the compressed
sensing (CS) classifier, positions identified by the mutual information (MI) classifier, and positions identified by the ensemble classifier (formed by combining the CS and
MI predictions) predicted to lie within the bnMAb epitope. The number of residues identified by the CS classifier, nCS, number of positions identified by the MI classifier,
nMI, number of positions predicted by the ensemble classifier, nENS, and number of positions identified by alanine scans, nEXPT, may differ between bnMAbs.
doi:10.1371/journal.pone.0080562.t001
Table 1. Cont.
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bnMAb epitopes for PGT 127, 128, and 130.
bnMAb CS classifier MI classifier Ensemble classifier Experiment
nCS position residue nMI nCS position residue nMI
PGT-127 18 136 Ser 2 332 2 332 4 301
169 Lys 334 334 303
188 Asn 332
230 Asn 334
290 Arg
297 Thr
322 Ile
330 His
332 Asn
334 Asn
334 Ser
373 Thr
442 Glu
674 Asn
792 Ala
815 Val
817 Ala
843 Val
PGT-128 23 82 Arg 2 332 2 332 1 303
133 Lys 334 334
151 Gln
152 Glu
153 Gln
229 Arg
230 Asn
289 Val
297 Thr
306 Arg
323 Ile
326 Ile
332 Thr
334 Ser
347 Asp
373 Thr
442 Glu
500 Glu
520 Leu
754 Pro
792 Ala
815 Val
817 Thr
PGT-130 18 49 Asp 2 471 1 792 7 301
151 Asp 792 303
230 Asn 307
297 Thr 309
300 Ser 324
360 Val 325
373 Met 423
Computational Prediction of HIV Antibody Epitopes
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Neutralization by PGT 125–128 and 130 is abolished by single
alanine substitutions of the N-linked glycan binding site at position
301, and/or position 303, which would also remove the glycan at
position 301, in the V3 loop of the JR-CSF isolate [51]. As
discussed above, PGT 126 and 127 neutralization activities are
also sensitive to alanine mutations removing the N-linked glycan at
position 332 [51].
Our algorithm did not identify position 301 for any of the five
bnMAbs, and failed to generate any predictions at all for PGT-
125. This result can be understood by considering the strains
tested in the pseudovirus panel. Of the 141 strains, only three
contained a residue other than Asn at position 301, and only six
contained a residue other than Thr at position 303. For a residue
to be identifiable as part of the functional epitope, the strains
within the panel must exhibit sufficient mutability at that position
for its impact on binding to be discernable above background
noise arising from experimental uncertainty and finite number of
measurements [50]. Numerical tests described in Materials and
Methods suggest that the minimum variability required for
detection of any single positions is on the order of 10 mutations
within the panel of 141 strains. This result is consistent with the
low variability of residues 301 and 303 in our virus panel
preventing our classifiers from identifying them as important
discriminants of neutralization activity for PGT 125 and 130. In
comparison, positions 332 and 334, where the latter is associated
with the N-linked glycan at position 332, were identified by our
algorithm for PGT 121, 123, 126, 127, and 135 (see above). These
residues are more highly variable within our panel, containing 28
and 40 non-Asn and non-Ser residues, respectively. A logo plot of
the variability of selected positions within the Env polyprotein
(Fig. 1) clearly illustrates the low variability of positions 301 and
303 relative to 332 and 334 within the 141-strain panel.
Three bnMAbs were sensitive to alanine substitutions removing
the N-linked glycan residue at 301, but not to those removing the
N-linked glycan at 332: PGT 125, 128 and 130. Despite the low
variability at residues 301 and 330, we note that our ensemble
classifier did not generate any false positives for PGT-125, and
identified only position 792 within the cytoplasmic domain of gp41
for PGT-130 [54]. Kalia et al. showed that point mutations in the
C-terminal tail caused conformational rearrangements in both
gp41 and – through non-covalent associations – gp120 [55]. These
conformational perturbations were sufficient to impair the
neutralization activity of certain antibodies whose epitopes lie
entirely within gp120, including the glycan-dependent bnMAb
2G12 [55,56]. It is conceivable therefore, that our classifier has
identified 792 as a position at which mutations may influence
PGT-135 binding efficiency by structural perturbations of the
binding site through non-covalent interactions. For PGT-128, our
classifier identified positions 332 and 334. As previously observed,
the crystal structure of PGT-128 bound to an engineered
glycosylated gp120 outer domain (containing a JR-FL mini-V3
loop) [52] supports these predictions, although these positions were
not sensitive to alanine mutations in the JR-CSF strain [51]. These
results illustrate the enhanced specificity – at the expense of
reduced sensitivity – of the ensemble classifier relative to either the
CS or MI classifier in isolation [38,48].
For PGT-130, our classifiers failed to identify other residues that
abolished neutralization in alanine scan experiments: viz., residues
307, 309, 324, 325, and 423 [51]. None of strains within our panel
contained Ala residues at any of these five positions. It is possible,
therefore, that the actual mutations present within the panel had a
weaker effect on bnMAb binding than a single Ala point mutation,
causing these positions to remain unidentified by our approach.
We also observe that positions 324 and 423 are very highly
conserved within the 141-strain panel (Fig. 1), where, as described
above, this low mutational variability impairs the ability of our
classifier to identify these positions as important determinants of
neutralization activity. None of these five positions are known
glycosylation sites [57].
PGT 143, 145:160 N-glycan Dependent bnMAbs
PGT 143 and 145 do not bind monomeric gp120 but recognize
the Env trimer. Indeed, PGT 143 and 145 target a quaternary
epitope similar to that defined for the bnMAbs PG9 and PG16
[51,58]. Our ensemble classifier identifies position 166 for PGT-
143, and positions 160 and 166 for PGT-145, both of which lie
within the V2 loop of gp120. Consistent with the evidence for a
Table 2. Cont.
bnMAb CS classifier MI classifier Ensemble classifier Experiment
nCS position residue nMI nCS position residue nMI
395 Cys
455 Glu
465 Thr
500 Glu
520 Leu
644 Asp
746 Ser
792 Ala
792 Leu
817 Thr
841 Leu
The experimentally identified positions are defined as those at which alanine point mutations were observed to increase the measured IC50 of the mutant by more than
30-fold relative to that of the wild type JR-CSF. Alanine scans were performed as part of the present work for PGT 143 and 145; data for PGT 121–135 were taken from
Ref. [51].
Footnote: See footnote to Table 1.
doi:10.1371/journal.pone.0080562.t002
Computational Prediction of HIV Antibody Epitopes
PLOS ONE | www.plosone.org 6 December 2013 | Volume 8 | Issue 12 | e80562Table 3. Compressed sensing (CS), mutual information (MI), and ensemble classifier predictions of HIV-1 Env positions constituting
bnMAb epitopes for PGT 135, 143, and 145.
bnMAb CS classifier MI classifier Ensemble classifier Experiment
nCS position residue nMI nCS position residue nMI
PGT-135 22 133 Ala 1 334 1 334 6 297
171 Thr 330
185 Ala 332
330 His 334
334 Ser 392
335 Asx 394
344 Gly
346 Ser
351 Ala
363 Ser
389 Gly
389 Lys
426 Leu
430 Ile
489 Ile
489 Val
733 Ile
733 Thr
752 Leu
815 Val
832 Gly
840 Val
PGT-143 16 47 Asx 1 166 1 166 2 160
51 Ser 166
166 Arg
167 Asp
171 Lys
182 Thr
240 His
252 Arg
252 Lys
269 Asx
360 Asn
389 Ser
491 Val
668 Asn
671 Asp
817 Ile
PGT-145 6 130 Asn 3 160 2 160 1 160
130 Lys 162 166
160 Asn 166
166 Arg
500 Lys
677 Asn
The experimentally identified positions are defined as those at which alanine point mutations were observed to increase the measured IC50 of the mutant by more than
30-fold relative to that of the wild type JR-CSF. Alanine scans were performed as part of the present work for PGT 143 and 145; data for PGT 121–135 were taken from
Ref. [51].
Footnote: See footnote to Table 1.
doi:10.1371/journal.pone.0080562.t003
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thought to be brought within close proximity at the apex of the
viral spike in the native heterotrimer [19,35].
To test these predictions we performed neutralization assays
using a JR-CSF pseudovirus incorporating single alanine substi-
tutions at positions 160 and 166. Substitutions at both of these
positions abrogated neutralization by PGT-143, resulting in
.6300 fold increases of the IC50 relative to wild type. Similarly
PGT-145 binding was abolished by an alanine substitution at
position 160, causing a .32,000 fold increase in the IC50 relative
to wild type; the substitution at position 166 had a more moderate
effect, resulting in a fold IC50 increase of only 6.4. Position 160 is
the site of an N-linked glycosylation that has been previously
implicated in the binding of bnMAbs PG9 and PG16 [58,59,60].
These data strongly suggest that this glycan, along with position
166, is also critical to formation of the epitope for PGT 143 and
145. A publication describing a detailed experimental study of
these bnMabs, of which these alanine scan data will form a part, is
forthcoming.
We observed that position 160 is rather highly conserved
relative to 166 (Fig. 1), and also that no strains within the viral
panel contained an Ala mutation at position 160. It is possible,
therefore, that compared to PGT-145, the actual mutations
present within the panel had a weaker effect on PGT-143 binding
than a single Ala point mutation at position 160, offering a
potential rationalization for why position 160 should have been
identified for PGT-145, but not PGT-143.
Comparison of the Ensemble Classifier to Predictions by
Fisher’s Exact Test
To assess the performance of our new approach in identifying
bnMAb epitopes, we compared its predictions to those of a
standard classification approach that has been previously used, for
example, to identify positions in gp120 subject to differential
selection pressure between two distinct HIV cohorts [61].
Specifically, we compared the distribution of amino acid residues
occupying a particular position over those strains in the panel that
are neutralized by the bnMAb, to the distribution over those
strains that are not. Point mutations at positions within the
bnMAb epitope are expected to have the largest impact upon
neutralization activity, and may therefore be identified as those
positions possessing a statistically significant difference between the
two distributions. Statistical significance is measured by Fisher’s
exact test [62], and the Benjamini–Hochberg false discovery rate
correction used to account for multiple testing [63]. The details of
the approach are presented in Materials and Methods, and the
predictions are compared to those of our ensemble classifier and
experimental alanine scan data in Table S3.
Specifying a significance threshold of a=5% for Fisher’s exact
test, the predictions of this approach are in good agreement with
those of our ensemble classifier for eight bnMAbs (PGT 125–128,
130, 135, 143, and 145). For PGT 121 and 123, however, it
exhibits very low specificity (high false positive rate), predicting 34
and 37 positions, respectively, as constituting the epitope, thereby
masking the true positives that are in agreement with experimental
data within a large number of false positives. It is necessary to
reduce the significance threshold to a=0.1% for Fisher’s exact test
to isolate the top two and three positions for PGT 121 and 123,
respectively, where we observe good agreement with our ensemble
classifier and alanine scan data. This stringent significance
threshold, however, severely compromises the sensitivity of the
test (high false negative rate), causing it to generate no predictions
at all for six bnMAbs (PGT 125, 127, 128, 130, 135, and 145).
Overall, although there are commonalities between the predictions
of the two approaches, our ensemble classifier does not suffer from
the poor specificity/sensitivity trade-off exhibited by Fisher’s exact
test, that results in poor predictions for some fraction of the
bnMAbs at different significance thresholds.
Discussion
We have presented a novel computational methodology for the
determination of amino acid residues that are the primary
discriminants of antibody neutralization activity for highly
antigenically variable viruses. Assuming that variations in neutral-
ization activity upon introducing mutations at these positions may
be attributed to modifications of antibody binding efficiencies, we
infer such residues to constitute key components of the antibody
functional epitope. Our approach marries techniques from
Figure 1. Logo plot of the variability of selected positions in HIV-1 Env within the 141-strain pseudovirus panel. We present data for
all positions identified in Tables 1–3 as significant determinants of bnMAb neutralization activity by either the ensemble classifier or experimental
alanine scan data.
doi:10.1371/journal.pone.0080562.g001
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designed to predict with high specificity those residues constituting
the epitope. It requires as an input experimental measurements of
neutralization activities against a panel of viral strains that are
typically collected as a matter of course in the characterization of
new bnMAb isolates. Our approach requires that the amino acid
sequences of the viral strains are known, but importantly, it does
not require any structural information. We anticipate this
approach to be valuable for systems where antigenic structures
do not exist, or are expensive to obtain.
We applied our approach to ten recently identified HIV-1
bnMAbs [51]. All bnMAbs considered in this work depend on
glycan chains covalently linked to the Env protein for the
formation of their epitopes. Prior experimental work has shown
binding of eight of the ten bnMAbs – PGT 121, 123, 125–128,
130, and 135– to be dependent on NXS/T-linked glycans at
positions 301/303 and/or 332/334 [51]. Experimental alanine
scan assays motivated by our computational predictions for the
remaining two bnMAbs – PGT 143 and 145– verified that the N-
linked glycosylation site at position 160 is implicated in antibody
binding.
We robustly identified the N-linked glycan associated with
positions 332 and 334 for the five bnMAbs for which alanine scans
showed this to be a primary determinant of neutralization activity
(PGT 121, 123, 126, 127, and 135) [51].
Insufficient mutability at positions 301 and 303 within our panel
of viral strains likely prevented the recovery of N-linked glycan
associated with these positions for the three bnMAbs for which its
importance has been experimentally demonstrated (PGT 125,
128, and 130) [51]. Encouragingly, in all three cases our ensemble
predictor showed high specificity and noise suppression charac-
teristics, declining to generate any predictions for PGT-125, only
one for PGT-130– position 792 in the C-terminal tail of gp41.
This finding is in line with published studies demonstrating that
non-covalently mediated perturbations of the gp120 structure due
to point mutations in the gp41 C-terminal tail were sufficiently
large to impair bnMAb binding efficiencies to the mutant [55].
For PGT-128 our ensemble classifier identifies the proximate N-
linked glycan associated with positions 332 and 334 for PGT-128.
These predictions for PGT-128 are supported by the crystal
structure of PGT 128 bound to an engineered glycosylated gp120
outer domain containing a JR-FL mini-V3 loop [52]. The alanine
scan was done on the JR-CSF isolate, and loss of neutralization in
this isolate by PGT 128 is only observed with the removal of at
least two of the three glycans in the binding site (N295, N301, and
N332) [64]. PGT 128 is distinct in that, for certain strains, this
bnMAb is able to pivot between binding N295 and N332 glycans.
This important functional aspect of PGT 128 illustrates strain
specific differences that only functional studies are able to
elucidate.
For the remaining two HIV-1 bnMAbs, PGT 143 and 145, our
algorithm predicted neutralization activity to be critically depen-
dent on positions 160 and 166 within the V2 loop of gp120. We
subsequently validated these predictions by collecting new
neutralization activity data for JR-CSF pseudoviruses incorporat-
ing single alanine substitutions at these positions. Our predictions
for these two newly isolated bnMAbs – that were subsequently
experimentally confirmed – present the new biological insight that
their epitopes are contingent on the N-linked glycosylation site at
position 160– a residue which has been previously implicated in
the binding of bnMAbs PG9 and PG16 [59] – and position 166,
which is not an N-linked glycosylation site [57].
By analyzing neutralization activity data against panels of viral
strains, and validating these predictions against new and existing
experimental data, we have demonstrated a new method to
systematically identify key residues constituting antibody epitopes
within the antigenic proteins of highly antigenically variable
viruses. In particular, the experimental validation by targeted
alanine scans of our de novo predictions of key epitope residues for
two newly isolated HIV-1 bnMAbs illustrates the predictive
capacity of our approach, and exemplifies its value in guiding and
accelerating experimental epitope identification. A deficiency of
the present approach is the inability of our approach to identify
positions that do not exhibit sufficient variability within the
pseudovirus panel [50]. Interestingly, ideas from compressed
sensing (the restricted isometry property of the pseudovirus panel,
cf. Materials and Methods) present a means to rationally design
additional strains with which to augment the panel, and enhance
recovery of the residues comprising the epitope [39,65,66].
Materials and Methods
Neutralization Assays
Cross-clade neutralization assays for the ten recently identified
HIV-1 bnMAbs PGT 121, 123, 125–128, 130, 135, 143 and 145
[51] were performed on a 108 virus panel using a single round of
replication pseudovirus and measuring entry into TZM-bl cells as
previously described in Ref. [67]. The measured IC50 values – the
antibody concentrations necessary to inhibit HIV activity by 50%
– were combined with previously reported measurements for an
additional 33 strains [51]. The IC50 measurements for the ten
bnMAbs against the 141-strain panel are presented in Table S1.
Measurements reported as ,0.001 mg/ml and .50 mg/ml
denote IC50 values outside the range of our experimental
resolution. In the application of our algorithms to this data, we
elected to hard-threshold these values to 0.001 mg/ml and 50 mg/
ml, respectively. Nucleotide sequences of the env gene correspond-
ing to each viral strain were downloaded from the NCBI
Nucleotide database (http://www.ncbi.nlm.nih.gov/nuccore) and
translated to yield the amino acid sequence of the corresponding
Env polyprotein.
Alanine Scans
Pseudoviruses incorporating HIV-1 JR-CSF single alanine
substitutions were produced as previously described [68]. The
neutralization assay of the PGT bnMAbs against HIV-1 JR-CSF
pseudovirus was measured by luciferase activity, using entry into
TZM-bl cells as described in Ref. [67].
Compressed Sensing Epitope Prediction
The binding affinity of each bnMAb towards each viral strain is
determined by the primary amino acid sequence of the Env
protein. Mutations at key residues within Env that are part of the
epitope of the bnMAb will reduce neutralization efficiency, and be
reflected in an elevated IC50 value. Each viral strain possesses a
different amino acid sequence, and the interaction of each bnMAb
with each of the 141 viral strains possesses a measureable IC50
value. Our goal is to data mine the 141 IC50 measurements using
our variable selection algorithms to determine those positions in
the Env protein where mutations have the largest impact on
neutralization activity for each bnMAb. We infer these residues to
be critical components of the conformational epitope of the
bnMAb.
We pre-processed the sequence data to remove from consider-
ation those among the 856 positions in Env at which the amino
acid type was fully conserved within all strains in the panel.
Positions at which the same amino acid residue is present in all
strains in the panel cannot, by definition, be identified by our
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196 residues from consideration. (As indicated in the Discussion,
additional strains may be added to the pseudovirus panel to
introduce mutational variability at conserved positions.) Further-
more, to suppress spurious effects arising from incomplete
experimental knowledge, we also eliminated those residues at
which more than 2.5% of strains harbored a residue of unknown
identity [69]. This operation eliminated a further 53 positions.
Together, these pre-processing steps removed 249 of 856 residues.
The amino acid sequence at the remaining 607 positions in each
viral strain was encoded as a 12,747-dimensional vector (21 amino
acid types 6 607 residues, where the 21
st amino acid ‘‘type’’
denotes a gap or residue of unknown identity) [70]. Each element
of this vector can take a value of 1 or 0, to indicate the presence or
absence of a particular amino acid type in a particular position.
The 141612,747 element matrix formed from the panel of n=141
viral strains was simplified by deleting those columns containing
only 09s (i.e., those amino acid types that were never observed at a
particular position within the panel of strains), to generate the
14163,021 element measurement matrix, W.
The n=141 element measurement vector, yk, was constructed for
each bnMAb, k, from the measured pIC50=–log(IC50) values from
the neutralization activity panel. As is conventional, we convert
measured IC50 values to ‘‘p-units’’ [70]. Assuming the residues
within the epitope to contribute additively to MAb binding, a
model for the neutralization activity of each bnMAb may be
formulated as a multivariate linear regression problem [70,71],
min
^ b bk
yk{W^ b bk
     
     
‘2
, ð1Þ
where ^ b bk is an estimate of the signal vector for bnMAb k, containing
the m=3,021 regression coefficients pertaining to each amino acid
type in each residue of the Env protein. Without loss of generality,
we choose to operate in a gauge in which the yk vector is centered
(
P n
i~1
yk(i)~0) and the columns of the measurement matrix, W, are
standardized (
P n
i~1
W(i,j)~0,
P n
i~1
W(i,j)
2~1) [72]. Standardization
of W places all regression coefficients on similar scales, irrespective
of the number of observations of each amino acid in each position.
As a linear transformation, this procedure does not affect the
predictive capacity of the inferred model, but rescales all
regression coefficients to be of the same order of magnitude.
Since the compressed sensing approach enforces sparsity by
penalizing large absolute values of the regression coefficients
constituting the elements of the signal vector, egalitarian
application of this penalization necessitates that the coefficients
be of similar magnitudes.
Mutations at the great majority of residues in Env will not affect
binding, with the amino acid identity at only a small number of
positions governing MAb binding affinity. Accordingly, the ‘‘true’’
signal vector for each bnMAb, bk, is expected to be sparse,
possessing only a small number, s,,m, of non-zero elements.
Compressed sensing (CS) exploits the anticipated sparsity of the signal
vector to permit its recovery from very few measurements [39,73],
making it is well suited to sparse signal recovery in the high
dimensionality-low sample size (HD-LSS), m..n, regime.
The restricted isometry property (RIP) of the measurement matrix, W,
may be loosely interpreted as the degree to which W preserves the
length of s-sparse vectors, and hence the capacity of the matrix to
faithfully ‘‘measure’’ sparse signals [39]. Adherence to the RIP
guarantees the recovery of any sparse signal within defined
mathematical bounds [39,65,66]. If one can manipulate the
sensing matrix – in the present case by augmenting the panel of
viral strains with additional engineered mutants – the RIP
provides a means to design a sensing matrix that guarantees
accurate recovery of s-sparse signals [73]. The RIP condition
provides a sufficient, but not necessary, condition for sparse signal
recovery, and, in practice, accurate recovery is generally achieved
if the number of non-zero elements of bk, s, is small compared to
its dimensionality, m [42,74].
Estimators of the sparse signal vector, ^ b bk, are computed by
solving the convex unconstrained optimization problem,
min
^ b bk
yk{W^ b bk
     
     
‘2
zt ^ b bk
     
     
‘1
, ð2Þ
where t is a non-negative coefficient, and the ‘p-norm of a vector
x is defined as x kk ‘p~
P
k
xk jj
p
   1=p
where xk jj denotes the
absolute value of the k
th element of the x vector [75]. To enforce
sparsity of the signal vector, ^ b bk, it would seem necessary to replace
its ‘1-norm in the second term of Eqn. 2– which sums the absolute
values of the elements of ^ b bk – with its ‘0-norm – which counts the
number of non-zero entries in the vector. No efficient algorithms
exist to solve the ‘0-norm problem, which is NP-complete and
numerically unstable [73]. However, fast algorithms do exist for
the ‘1-norm problem, the solution to which recovers ‘0-norm
solution with overwhelming probability under the mathematically
precise conditions specified by the RIP [39,65,66]. This remark-
able result lies at the heart of practical applications of the
compressed sensing methodology [73]. As observed above, in
practice, accurate recovery of sparse signals is achieved if the
number of non-zero elements of bk, s, is small relative to its
dimensionality, m [42,74].
For efficient solution, the problem in Eqn. 2 may be
reformulated as a ‘1-regularized linear least-squares quadratic
programming problem,
min
^ b bk
yk{W^ b bk
     
     
‘2
s:t: ^ b bk
     
     
‘1
ƒt, ð3Þ
where t is a non-negative parameter [75]. Solutions to Eqn. 3 are
efficiently provided by the LASSO algorithm [39,75,76]. The ‘1-
constraint enforces sparse solutions to the ‘2 regression problem,
with signal vector, ^ b bk
, becoming progressively less sparse as t is
increased from zero [72]. From a Bayesian perspective, the ‘1
penalty corresponds to the adoption of a Laplacian prior
distribution on the regression coefficients [53]. Appropriate values
of t – or, equivalently, the number of non-zero elements in ^ b bk –
may be specified by identifying a knee in the ‘2 reconstruction
error [77], or by cross-validation [78]. At sufficiently large t, the
regularization constraint becomes inactive, and the signal vector,
^ b bk t~? ðÞ , is precisely that obtained from ordinary least squares
[72]. In the present work, the LASSO optimization defined by
Eqn. 3 was solved using an in-house modification of a MATLAB
implementation of the LARS algorithm [72,79]. Signal vectors,
^ b bk(t), were computed along the entire LASSO path as t was
increased from zero and the signal vector became progressively
less sparse.
Non-zero elements in ^ b bk identify particular residues in
particular positions that are the principal discriminants of bnMAb
neutralization activity. In this manner, we employ compressed
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residues that constitute bnMAb functional epitopes on Env. To
determine an appropriate number of variables (i.e., non-zero
elements of ^ b bk) to retain in the regression model, we constructed
plots of the mean squared error (MSE) and leave-one-out cross
validation mean squared error (LOO-CV MSE) as a function of
the sparsity of ^ b bk.
The MSE, yk{W^ b bk
     
     
‘2
, provides a measure of the predictive
capacity of the fitted model, and typically decreases as more
variables are incorporated into the model. We anticipate that a
small number of variables – the key residues within the bnMAb
epitope – will be capable of explaining most of the variance in the
measured IC50 values, and therefore expect to observe a knee in
the MSE curve, where an initially rapid decrease transitions to a
more gradual decay (cf. Fig. 2a). The location of the knee may be
used to infer an appropriate number of variables to retain in the
model, and may be systematically identified using, for example,
the L method of Salvador and Chan [77]. (We note that it is
possible for non-zero elements of ^ b bkz to shrink back to zero as t
increases, giving rise to non-unique solutions for ^ b bk at a particular
level of sparsity [72]. In such cases, we select the solution with the
lowest MSE value.).
Cross validation, here leave-one-out cross validation (LOO-
CV), provides a tool to assess overfitting, offering a complementary
means to infer an appropriate number of variables to retain. This
analysis proceeds by removing from consideration each observa-
tion in turn from within the n=141 element measurement vector,
yk, and recomputing the LASSO path by solving Eqn. 3 over
the remaining n=140 observations. The squared error between
the measured IC50 value removed from the data set, and its
prediction using the refitted model is then recorded at each level of
sparsity of ^ b bk. The LOO-CV MSE is defined as the average of
the squared errors at a particular level of sparsity computed over
the removal of each of the n=141 elements of yk in turn. We note
that under this protocol, the precise variables included in the
regression model at a particular level of sparsity may differ for
different 140-observation subsets of the n=141 element measure-
ment vector.
In general, the LOO-CV MSE decreases as more variables are
included and the regression model is better able to fit the data,
then passes through a minimum and increases as models
incorporating large numbers of variables begin to overfit the data.
For all ten bnMAbs considered in this work, we observed
the LOO-CV curves to possess relatively shallow minima preceded
by relatively pronounced knees (cf. Fig. 2b). Accordingly, we
employed the L method [77] to systematically locate the knees
observed in both the MSE and LOO-CV MSE curves, and
took the mean of these two values as the appropriate number
of residues (i.e., non-zero elements of ^ b bk) to identify for each
bnMAb.
Mutual Information Epitope Prediction
Given the panel of n=141 viral sequences, we compute for each
position, a, the probability of observing each of the 20 amino
acids, xi, i~1...20, denoting this quantity as p(xa
i ). The entropy of
the random variable Xa indicating the identity of the amino acid
at position a is defined as [44],
Figure 2. Compressed sensing (CS) selection of PGT-123 epitope residues. Results of the application of the compressed sensing
classification algorithm to the neutralization activity of bnMAb PGT-123 against a panel of 141 HIV-1 pseudoviruses (cf. Table S1). In each panel, the
abscissa indicates the number of non-zero elements in the ^ b bk signal vector computed by the LASSO algorithm, and therefore the number of residues
incorporated into the regularized least squares fit of the neutralization data (Eqn. 3). For clarity of viewing, plots are terminated at the 100-
component model. As indicated by the arrows, knees in the (a) mean squared error (MSE) over the complete data set and (b) leave-one-out cross-
validation mean squared error (LOOCV-MSE) curves were identified using the L method at 11 and 9 residues, respectively [77]. The mean of these
values motivated the selection of the ten residues constituting this model: I323, H330, N332, N334, S334, S612, N671, Q740, V815, and V843 (c.f.
Table 1).
doi:10.1371/journal.pone.0080562.g002
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X 20
i~1
p(xa
i )logp(xa
i ) ð4Þ
Since the mutual information framework is most naturally
applied to discrete, rather than continuous, variables, we chose to
define a cutoff in the neutralization activity of each bnMAb.
Motivated by the range of measured IC50 values reported for
existing HIV-1 bnMAbs [51,59], we defined an IC50 cutoff of
10 mg/ml. We demonstrate in Table S4 that our predictions for
key residues in bnMAb epitopes are robust to the precise value of
this parameter. The cutoff permitted us to discretize the IC50
measurements for each bnMAb, k, against the panel of viral strains
into a vector of random variables, Zk, where zk
1~1 denotes a
strong neutralizing activity (IC50,10 mg/ml) of bnMAb k against
a particular viral strain, and zk
0~0 indicates a weak response.
In an analogous manner to Eqn. 4, we define the entropy of the
random variable Zk describing the neutralization activity of
bnMAb k as,
H(Zk)~{
X 1
i~0
p(zk
i )logp(zk
i ) ð5Þ
By extension, the joint entropy of Xa and Zk, is defined as,
H(Xa,Zk)~{
X 20
i~1
X 1
j~0
p(xa
i ,zk
j )logp(xa
i ,zk
j ) ð6Þ
and the conditional entropy of Zk with respect to Xa as,
H(ZkjXa)~{
X 20
i~1
X 1
j~0
p(xa
i ,zk
j )logp(zk
j jxa
i ) ð7Þ
Finally, the mutual information is given by,
MI(Xa,Zk)~H(Xa)zH(Zk){H(Xa,Zk)
~H(Zk){H(ZkjXa):
ð8Þ
Eqn. 8 shows that the mutual information may be regarded as a
measure of the reduction in the uncertainty in the neutralization
activity of bnMAb k, given knowledge of the amino acid identity at
Env position a.
In practice, we choose to work with a normalized form of the
mutual information, known as the redundancy,
R(Xa,Zk)~
MI(Xa,Zk)
1
2
H(Xa)zH(Zk) ½ 
: ð9Þ
Normalization of the MI in this manner has been shown to
improve the predictive power of information theoretic predictions
of protein contact residues [46]. The redundancy also possesses the
attractive feature of being bounded between 0 and 1, with a value
of R(Xa,Zk)~0 indicating that knowledge of the residue identity
at position a has no impact on our ability to predict the
neutralization activity of bnMAb k. At the other extreme, a one-
to-one correspondence between residue identity and neutralization
activity implies R(Xa,Zk)~1, indicating that predictions may be
made with 100% accuracy. To suppress artifacts arising from
incomplete experimental knowledge, in practical calculations with
Eqn. 9 we neglect those among the n=141 sequences for which
the residue type at position a is unknown, or a gap exists.
For each bnMAb, k, we compute R(Xa,Zk) for each of the 607
positions, a, in Env. (As described above, the 249 positions that are
either fully conserved within all viral strains in the panel, or
contain an unknown residue in more than 2.5% of strains, were
eliminated from consideration). The positions are rank ordered to
produce a non-ascending spectrum of R(Xa,Zk) values [40].
Knowledge of the amino acid identity at the positions constituting
the bnMAb functional epitope is expected to lead to a large
decrease in the uncertainty in the neutralization activity, and these
positions should therefore possess high redundancy values.
Conversely, the majority of positions should not contain high
information content about the measured neutralization capacities.
To systematically identify which redundancy values are
statistically significant, and therefore which positions should be
selected by the MI classifier, we estimate from our data the
spectrum of R(Xa,Zk) values that would be expected in the
absence of correlations between neutralization activity and the
residue identity in each position. We empirically construct a null
model lacking these correlations by aligning all n=141 the viral
sequences, each containing 607 positions, into a 1416607 matrix,
and randomly and independently permuting each column. The
effect of this operation is to shuffle the identity of each amino acid
at each position among the n=141 strains, breaking correlations
between neutralization activity and residue identity. Since the
probability of observing each amino acid residue at each position
is unaltered by shuffling, H(Xa) and H(Zk) remain unchanged,
whereas H(Xa,Zk), and therefore MI(Xa,Zk) and R(Xa,Zk), are
affected by breaking these correlations. We then compute the
R(Xa,Zk) value for each position. We perform this shuffling
operation ten times for each bnMAb to construct an empirical
distribution of R(Xa,Zk) values in the absence of correlations. The
maximum R(Xa,Zk) value, Rcutoff, detected by this procedure
represents an estimate of the largest redundancy expected to arise
under the null hypothesis that the neutralization activity and
amino acid identities are uncorrelated. R(Xa,Zk) values computed
from the original (unshuffled) data that are larger than Rcutoff
correspond to positions for which there is statistically significant
correlation between the amino acid identity and neutralization
activity. These positions are extracted as our MI classifier
predictions of the key residues within the bnMAb epitope.
In Fig. 3 we present the redundancy values computed from the
unshuffled data for bnMAb PGT-123, along with a dashed line
indicating Rcutoff computed by our shuffling procedure. In this case,
the MI classifier identified three positions – 332, 334 and 330 – as
statistically significant predictors of neutralization activity.
Ensemble Classifier
Combining the predictions of classification algorithms into a
single ensemble classifier is an established means to suppress noise
and improve classification performance [38,47,48]. In the present
case, we employ positive unanimity voting,o rconsensus prediction,t o
improve the prediction specificity at the cost of reduced sensitivity
[38,48]. Accordingly, we predict a position to form part of the
bnMAb epitope only if it is identified by both the compressed
sensing and mutual information algorithms. The ensemble
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either of the two classification algorithms alone, resulting in
improved confidence that the identified residues represent true
positives, at the expense of an elevated rate of false negatives [38].
This choice is consistent with the stated goal of this work to
localize bnMAb epitopes to a small number of critical positions,
rather than as a means to predict all residues constituting the
conformational epitope.
As an example of the residue selection protocol, we present the
results of the CS and MI classification algorithms for bnMAb
PGT-123. In Fig. 2 we show the CS classifier MSE and LOO-CV
curves, both of which exhibit a steep decline to a conspicuous knee
as the first ten residues are incorporated into the model. Beyond
this point, the MSE decays more gradually, and the LOO-CV
MSE passes through a shallow minimum at the 27-residue model.
Application of the L method to these curves identified a knee in
the MSE and LOO-CV curves at 11 and 9 residues, respectively
[77]. Taking the mean of these values motivated us to select a ten-
component model using the CS classifier, corresponding to the
selection of residues: I323, H330, N332, N334, S334, S612, N671,
Q740, V815, and V843 (cf. Table 1). We note that although the
minimum in the LOO-CV curve suggests that a 27-component
model may be constructed without overfitting the data, the more
parsimonious 10-component model accounts for 82% of the
reduction in the cross validation error in moving from a one to 27-
component model. In Fig. 3 we show the MI classifier redundancy
spectrum. The shuffling procedure described above identified
redundancy values above Rcutoff=0.15 to be statistically significant,
motivating the selection of the three top ranked positions using the
MI classifier: 332, 334, and 330 (cf. Table 1). Observe that while
the CS classifier identifies specific residues in particular positions
as primary discriminants of neutralization activity, the MI
algorithm identifies only positions. Combining these two sets of
predictions, the ensemble classifier identifies positions 330, 332,
and 334 as forming part of the PGT-123 epitope.
Epitope Prediction by Fisher’s Exact Test
For each bnMAb we used the same IC50 cutoff of 10 mg/ml
employed by our MI classifier to partition the sequences in our
141-strain panel into those that were neutralized by the bnMAb,
and those that were not. For each of the 856 positions in Env, we
compiled two histograms of the observed distribution of amino
acid residues: one over the neutralized sequences, and another
over the unneutralized sequences. It is the anticipation that point
mutations within the bnMAb epitopes will most strongly influence
neutralization activity, and should therefore exhibit the largest
differences in the observed amino acid residue distributions
between the neutralized and unneutralized sequence ensembles.
Employing Fisher’s exact test [62] we then assigned a p-value to
the null hypothesis that each pair of histograms for each position in
Env were drawn from a common underlying distribution. (Due to
small sample sizes and highly unequal representations of amino
acid residues at each site, Fisher’s exact test is a more appropriate
test than the two-sample chi-squared test [62].) Specifying
significance levels of a=5%, 1% and 0.1%, we applied the
Benjamini–Hochberg false discovery rate correction to account for
multiple testing [63] to identify for each bnMAb those residues for
which differences in the observed amino acid residue distributions
reached the significance threshold. These positions are predicted
to form part of the bnMAb epitope. A comparison of these
Figure 3. Mutual information (MI) selection of PGT-123 epitope positions. The redundancy spectrum produced by application of the
mutual information classification algorithm to the neutralization activity of bnMAb PGT-123 against a panel of 141 HIV-1 pseudoviruses (cf. Table S1)
using an IC50 cutoff of 10 mg/ml. The ordinate records the computed redundancy of the residue identity in each position with the observed
neutralization activity. The abscissa lists the positions of the protein in decreasing order of redundancy. The dashed line indicates the cutoff
computed by the shuffling procedure described in Materials and Methods, Rcutoff=0.15, above which redundancy values should be considered
statistically significant. These results suggest that the three top ranked positions – respectively, 332, 334 and 330– be retained in the model (cf.
Table 1). For clarity of viewing, plots are terminated at the 100-component model.
doi:10.1371/journal.pone.0080562.g003
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experimental alanine scans are presented in Table S3.
Estimation of Minimum Residue Variability Required for
Detection
We have suggested that the high conservation of residues at
positions 301 and 303 may be responsible for the inability of our
classifiers to detect the N-linked glycan at position 301 for the five
bnMAbs (PGT 125–128 and 130) for which alanine scans indicate
it to be an important discriminant of binding. To test this claim,
and estimate the minimum variability required for detection, we
constructed and analyzed a synthetic data set as described below.
For simplicity, we make our estimate using only the MI classifier,
for which the binary classification criterion (neutralized vs.
unneutralized) makes generation of synthetic data straightforward,
since it does not require the specification of quantitative IC50
values.
The mean number of the n=141 strains neutralized (i.e.,
IC50,10 mg/ml) by each of the 10 bnMAbs is 78, and the mean
value of Rcutoff calculated using the shuffling protocol is 0.12.
Using these figures we constructed a synthetic data set consisting of
141 viral strains, each consisting of a single amino acid residue that
may take on one of two identities: wild type or mutant. Of the 141
strains, 78 were considered neutralized by a hypothetical bnMAb,
and 63 unneutralized. If the strain is neutralized, the residue was
mandated to be wild type. If the strain is not neutralized, the
residue can be either wild type or mutant. The question we wished
to answer was: How many of the non-neutralized strains must
contain a mutant amino acid for the redundancy calculated by the
MI classifier to breach Rcutoff=0.12? By varying the number of
mutant residues, we determined that 10 mutations within the 141-
strain panel are required for detection by the classifier, providing
an empirical estimate for the minimum amino acid variability
required for detection within the pseudovirus panel.
This result is numerically consistent with the observation that
the N-linked glycan associated positions 301 and 303 that were
undetectable by our classifier contained only three and six
mutations, respectively, whereas the N-linked glycan positions
332 and 334 containing 28 and 40 mutations, respectively, were
detectable by our approach.
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Table S2 Ensemble classifier predictions of positions of HIV-1
Env positions constituting bnMAb epitopes using randomly and
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positions with statistically significant differences in the observed
distribution of amino acid residues in the neutralized
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